StemCell Therapy

Neuropathic pain Growth 2021-2030, Covid19 Outbreak Impactresearch report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. It places the market within the context of the wider neuropathic pain, and compares it with other markets., market definition, regional market opportunity, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, neuropathic pain size forecast, market data & Graphs and Statistics, Tables, Bar &Pie Charts, and many more for business intelligence.Getcomplete Report (Including Full TOC, 100+ Tables & Figures, and Chart). In-depth Analysis Pre & Post COVID-19 MarketOutbreak Impact Analysis &Situation by Region

The global neuropathic pain market is expected to exhibit a growth rate of 6.06% CAGR during the forecast period 2018- 2023.

A release on June 8th, 2021, by the Bureau and Economic Analysis and U.S. The Census Bureau reports the recovery of the U.S. market. The report also described the recovery of U.S. International Trade in July 2021.In April 2021, exports in the country reached $300 billion, an increase of $13.4 billion. In April 2021, imports amounted to $294.5 billion, increasing by $17.4 billion. COVID19 is still a significant issue for economies around the globe, as evidenced by the year-over-year decline in exports in the U.S. between April 2020 and April 2021 and the increase in imports over that same period of time. The market is clearly trying to recover. Despite this, it means there will be a direct impact on the Healthcare/ICT/Chemical industries, resulting in a large market forNeuropathic pain.

Neuropathic pain is generally caused by the peripheral nerve disorder. The higher demand for better treatment methods for pain is hopefully expected to augment the growth of the global neuropathic pain market during the forecast period 2018- 2023. Also, factors such as the introduction of the pain management centers along with higher demand for generic drugs for eliminating the higher levels of pain is anticipated to boost the growth of the global neuropathic pain market.

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=31837

Market segmentation

Based on its type, the global neuropathic pain market is bifurcated into entrapment neuropathy, peripheral neuropathy, post traumatic neuropathy, post herpetic neuralgia (PHN), phantom limb pain, and trigeminal neuralgia. On the basis of its indication, the market is divided into diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and spinal stenosis. Based on its diagnosis, the market is segmented into blood tests, imaging, and physical examination. On the basis of its treatment, the market is classified into medication type and multimodal therapy. Major end-users include clinics, hospitals, and research organizations. Lastly, on the basis of its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.

Regional analysis

Geographically, the global neuropathic pain market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others are some of the major players in the global neuropathic pain market.

Table of Contents:Market Overview Market Dynamics Associated Industry Assessment Market Competitive Landscape Analysis of Leading Companies Market Analysis and Forecast, By Product Types Market Analysis and Forecast, By Applications Market Analysis and Forecast, By Regions Conclusions and Recommendations Appendix

Access full Report Description, TOC, Table of Figure, Chart, etc. @https://reportocean.com/industry-verticals/sample-request?report_id=31837

Our market research provides vital intelligence on market size, business trends, industry structure, market share, and market forecasts that are essential to developing business plans and strategy.

A combination of factors, including COVID-19 containment situation, end-use market recovery & Recovery Timeline of 2020/ 2021

Under COVID-19 Outbreak Impact Analysis:We analyzed industry trends in the context of COVID-19. We analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets. We analyze the impact of COVID-19 on various regions and major countries.The impact of COVID-19 on the future development of the industry is pointed out.

The Study ExploreCOVID 19 Outbreak Impact AnalysisWhat should be entry strategies, countermeasures to economic impact, and marketing channels? What are market dynamics? What are challenges and opportunities? What is economic impact on market? What is current market status? Whats market competition in this industry, both company, and country wise? Whats market analysis by taking applications and types in consideration?

Key questions answered:Study ExploreCOVID 19 Outbreak Impact Analysis

The study objectives of this report are:To study and analyse the global market size (value & volume) by company, key regions/countries, products and application, history data, and forecast to 2025. To understand the structure of market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global manufacturers, to define, describe and analyse the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyse the growth trends, future prospects, and their contribution to the total market. To project the value and volume of submarkets, with respect to key regions (along with their respective key countries). To analyse competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies.

Request Full Report-https://reportocean.com/industry-verticals/sample-request?report_id=31837

What is the key information extracted from the report?

Geographical Breakdown:The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery path of Covid 19 for all regions, key developed countries and major emerging markets.

Countries:Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam

In-Depth Qualitative COVID 19 Outbreak Impact Analysis Include Identification And Investigation Of The Following Aspects:Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces. The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios. The report basically gives information about the Market trends, growth factors, limitations, opportunities, challenges, future forecasts, and details about all the key market players.

Request Full Report-https://reportocean.com/industry-verticals/sample-request?report_id=31837

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Report Ocean:

Email:sales@reportocean.com

Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.reportocean.com/

See the original post here:
Neuropathic pain Market Overview By Share, Size, Industry Players, Revenue and Product Demand 2021-2030 The New York Irish Emgirant - The New York...

An Exeter optometrist whose diagnosis saved a womans sight is raising awareness about the importance of eye tests. Emily Beard, who works at the Specsavers Exeter store, assessed a 33-year-old woman whose sight was deteriorating.

As part of an extensive eye examination Emily used a hospital-grade optical coherence tomography (OCT) machine to look at the womans eyes and what she saw concerned her, so she urgently referred the woman to the Royal Devon and Exeter Hospital. They immediately did an MRI scan and found a tumour pressing down on her optic nerves. The woman was transferred to Derriford Hospital in Plymouth, where she underwent a seven-and-a-half-hour operation to remove a tumour behind her eyes.

Emily says: "This is a prime example of the importance of eye tests. Theyre not just about updating the prescription. An eye test can help detect all sorts of issues. In this case, the woman came in complaining of patches of her vision going blurry. Shed been seen elsewhere but they didnt seem to know the problem. She was missing most of her field of vision in her eye, which suggested to me that something was pressing on her optic nerve, which is very serious, so I referred her to hospital straightaway."

The woman, who does not want to be named, presented Emily with flowers and chocolates as a thank you. She says: "I cant express my appreciation to Emily enough for what she did for me. Her diagnosis was spot on and she saved my sight. Without her Id have carried on assuming my symptoms were just stress-related and I would have eventually gone blind. Emily is an absolutely amazing optometrist and I will always remember what she did for me.

"After she referred me, it all happened so fast. It was such a delicate operation and Derriford didnt know what my sight would be like afterwards. If Id gone to Specsavers earlier it wouldnt have been such a long operation. So, of course, if I knew what I know now, I would have gone to Specsavers straightaway, because without their diagnosis I wouldve gone completely blind because the tumour was wrapped around the right optic nerve and was doing the same to the left. I wanted to see my niece grow up I was desperate for that and thanks to Specsavers and the hospitals, I can do that."

Specsavers recommends that everyone should have an eye test at least once every two years, and more often if they notice any changes to their vision or eyes. Emily adds: Its great to hear that the operation all went well. Its outcomes like this that made me want to be an optometrist, knowing what a difference a diagnosis can make to someone. It also shows how important eye tests are, because if something serious is found people can get treatment early, and that can be crucial.

"In this case, the woman wasnt in any pain. Often people can go on thinking theyre fine when really theyre not, so they should get themselves checked out, because the technology we have now can pick up things that even the best optician might not see, and that can save your sight or even your life.

To book an appointment at Specsavers Exeter, visit the store at 247-248 High St, telephone 01392 210604 or go online at http://www.specsavers.co.uk/stores/exeter.

Get all the latest from DevonLive sent straight to your inbox by signing up to our newsletters here.

See the article here:
Blurry vision turned out be tumour behind Exeter woman's eye - Devon Live

Sonia Dawswell's weight loss journey, pictured in 2005 and now. (Collect/PA Real Life)

A woman who lost half her body weight and then put much of it back on due to the debilitating affects of losing her sight and not being able to cook has managed to shed the pounds once again.

Sonia Dawswell, 54, who stands at 5ft 3, was 21st and a UK size 28 when she decided to make a change before a holiday to Tenerife in 2005. "I was getting on a plane with a friend and caught sight of myself in the glass," she says.

"I just thought, 'Oh my god!' I hadn't realised how big I really was.

"I said to my friend there and then that I'd have a great holiday, eat what I wanted, come back and make some changes."

Sonia Dawswell pictured here in 2004. (Collect/PA Real Life)

Upon joining WW (previously Weight Watchers), Dawswell had a BMI of 52, compared to the NHS' suggested healthy range of 18.5-24.9.

Dawswell, a court volunteer from East London, then slimmed down to 10st 7lb and a size 12/14 with a BMI of 26.

Dawswell, who has suffered with sight issues all her life (her mum first noticed problems with her vision when she was just a toddler), gradually began needing stronger and stronger glasses as she grew older, which eventually led her to being registered partially sighted due to cataracts (when the lens in your eye develops cloudy patches) and glaucoma (a common eye condition where the optic nerve becomes damaged).

Read more: Rebel Wilson sets those weight loss rumours straight: 'That was NEVER my diet'

Sonia Dawswell after she lost 10st 7lbs. (Collect/PA Real Life)

Then, one night in 2018, she completely lost sight in her left eye. The scary turn of events meant she was now registered as blind, a disability that affected her every aspect of her life, including not being able to cook.

"I went to bed with sight, woke up completely blind in my left eye," recalls Dawswell, who lives alone.

"As I only have a small amount of sight in my right eye, it made everyday tasks impossible."

She had to rely on pre-packaged or takeaway food and found herself having "endless snacks all day long".

Story continues

"There was no end to it," she says. "Id just be picking from morning to night. Crisps, biscuits, sandwiches. Anything I could just buy and eat. I couldnt even see the calories on the back of the pack.

On my way home from work, Id stop off at the chip shop, get chips and eat them at home with a cheese and onion pasty.

Watch: Blind girl scores playing basketball game in front of huge crowd

Dawswell candidly added, "Ive been to lots of support groups for people with sight loss and a lot of us are overweight. I believe were dying sooner because of it.

Nevertheless, Dawswell has never let her visual impairment hold her back. "It doesn't prevent me from socialising, or working, and I wasn't going to let it stop me going to WW." It also never stopped her from enjoying her love of fashion, taking friends shopping with her or asking shop assistants to guide her to clothes in favourite colours.

Sonia Dawswell before her weight loss. (Collect/PA Real Life)

"Back then, I was always the biggest women in the room," she says. "But I'd always be a well-dressed big woman!"

It was during lockdown, when she was also unable to exercise and eating as described, that Dawswell noticed herself putting on weight again.

I never got back to that 21st, but I did gain a lot of weight back. There was nothing to do but sit and eat. No way to exercise.

Coming out of lockdown, she was 15st 7lb and a size 18, giving her a BMI of 38.4. Having confidence in the WW diet which had helped her so well before, Dawswell recommitted to losing the weight again.

Read more: Woman loses 13 stone without ditching carbs: 'I was a heart attack waiting to happen'

Sonia Dawswell after her weight loss. (Collect/PA Real Life)

Dawswell also began walking six miles a day, stopped eating after 7pm and cleverly figured out ways to learn to use some appliances in the kitchen again, like a blender and frying pan, despite the difficulty she faced due to her impaired eyesight. This helped her make herself omelettes and healthy breakfast smoothies, with her diet now also including fruit or porridge, or a butternut squash salad.

Her friends also stepped up to support her determination, dropping off food and giving words of encouragement as she not only set out to lose weight, but look after herself day to day.

Read more: 'I did for for myself and not anyone else': Adele on her body transformation

Sonia Dawswell now has three healthy meals a day, walks 10,000 steps six days a week and snacks on fruit instead of crisps. (Collect/PA Real Life)

"I learnt tricks like using appliances with big, simple buttons," she explained. "I'd go to the supermarket, take pictures of the back of packets and enlarge them on my phone, so I could work out the points."

Dawswell has lost 4st and is 11st 6lb and a size 14 just half a stone from her goal weight since rejoining WW and committing to exercise every day.

As a lover of bright and beautiful colours, she can now buy a wider range of stylish clothing and again and feels healthier and happier though of course 'stylish' clothing should accommodate all sizes.

"I hope my story can encourage other people," she emphasised. "I'm a woman of a certain age and menopausal, but that hasn't stopped me. I have visual impairment but that hasn't stopped me either."

"I want people to realise you can have a life with a disability and still watch your weight. It's not easy but keep knocking on those doors until they open for you."

Sonia Dawswell now wears a size 14. (Collect/PA Real Life)

Additional reporting PA.

Link:
Woman who lost half her body weight sheds the stones for second time after sight loss - Yahoo News

A high-school student who experienced nausea was later diagnosed with an aggressive and deadly brain tumor.

The boy, who has only been identified by his first name, Tom, was told by doctors that he had glioblastoma multiforme (GMB) when he was just 13 years old, the Liverpool Echo reported.

Glioblastoma multiforme is an aggressive form of cancer that can occur in the brain or spinal cord. It forms from star-shaped cell cells known as astrocytes that are found in the nervous system.

While this cancer affects people of any age, it occurs more frequently in older adults and is uncommon in children, according to the Mayo Clinic.

Figures from a 2017 publication show that the incident rate of GMB is just over 3 per 100,000 people in the United States, with the median age of cases being 64.

Among the symptoms of GMB are nausea, vomiting, persistent headaches, seizures, double or blurred vision, and changes in mood or personality.

This form of cancer can be very difficult to treat, with the average survival time being 12-18 months, according to U.K.-based The Brain Tumour Charity. Only a quarter of glioblastoma patients survive more than one year, while only 5 percent survive more than five years.

Treatments may be able to slow the progression of the disease. These can include surgery, followed by chemotherapy and radiotherapy.

Tom, now 14, who lives in Ellesmere Port, northwestern England, began feeling sick in September 2020 after returning to school following the U.K.'s first national COVID lockdown.

The boy's mother told the Echo she first thought her son's health problems were linked to his return to school. But he began to experience further complications.

"I contacted doctors a few times. When he was off for school holidays in October he said he had double-vision," the 47-year-old, who was only identified by her first name, Karen, told the Echo.

"He had a doctor's appointment at the end of October and they said physically he was OK. He suffered a really bad migraine at the beginning of November so I contacted the opticians thinking it was his eyes due to being on computer a lot more," she said.

The boy underwent an eye test, during which the optician spotted a swelling behind his eye. He was sent to hospital where an MRI scan revealed that he had a brain tumor.

"Tom was physically shocked, I was in pieces," the mother said.

The boy was transferred by ambulance to Alder Hey Children's Hospital, where he underwent surgery, although doctors told the family that they would not be able to remove the whole tumor. A week after the surgery, Tom was diagnosed with grade 4 glioblastoma multiforme.

In December 2020, the boy began radiotherapy and chemotherapy, but he lost his peripheral eyesight due to pressure on his optical nerve.

After six weeks of radiotherapy and chemotherapy once a month for a year, doctors told the family that treatments were no longer working and there is nothing more they could do, according to a GoFundMe page set up by the mother.

"Tom has always been a positive person and the way he has handled this devastating news at such a young age is absolutely amazing and he is my hero," the mother said on the GoFundMe page.

"We are as a family determined to fight this as hard as we can and be in the 2 percent that survive this horrible aggressive cancer," she said.

The mother said she was trying to raise money to try and get her son onto a clinical trial in Germany or the U.S. to give him the "the best fighting chance at life."

See the rest here:
High Schooler's Nausea Turned Out To Be Aggressive and Deadly Brain Tumor - Newsweek

Prevent Blindness provides free, dedicated resources to encourage proper eye protection from negative effects of UV

CHICAGO, April 25, 2022 /PRNewswire-PRWeb/ -- As the warmer weather begins to encourage more outdoor activities, Prevent Blindness, the nation's oldest eye health and safety organization, has declared May as Ultraviolet (UV) Awareness Month. The nonprofit group is seeking to educate the public on the negative effects of UV exposure to the eyes and vision, offering a dedicated webpage, PreventBlindness.org/sun-and-vision, downloadable fact sheets and shareable social media infographics.

There are two types of UV rays: UV-A and UV-B. Over time, the effects of UV rays may help cause a number of eye problems. UV-A rays may affect central vision. They can damage the macula, a part of the retina at the back of the eye. The front part of the eye (the cornea and the lens) absorbs most UV-B rays, but these rays may cause even more damage to the eyes than UV-A rays.

According to the Wilmer Eye Institute and Johns Hopkins Medicine, corneal damage, cataracts and macular degeneration are all possible chronic effects from UV exposure and can ultimately lead to decreased vision. Additionally, UV light is associated with skin cancers including squamous cell carcinomas, basal cell carcinomas, and cutaneous melanoma. Squamous cell carcinoma can occur not just on the skin, but on the conjunctiva and invade the cornea and inside of the eye, in some cases necessitating removal of the entire eye.

The Hidden Dangers of UV: Keeping Your Eyes Safe report from The Vision Council lists factors that put people's eyes at greater risk of damage from UV exposure, including:

Prevent Blindness strongly recommends wearing UV-blocking sunglasses as well as a brimmed hat to provide the best protection against UV rays. Sunglasses should:

"Spending time outdoors offers many health benefits. We encourage adults and children to wear the proper UV protection for their eyes to keep them safe and healthy today, and in the years to come," said Jeff Todd, president and CEO of Prevent Blindness.

For more information on UV eye protection, please visit the Prevent Blindness dedicated webpage at PreventBlindness.org/sun-and-vision, or call (800) 331-2020.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram and LinkedIn.

Media Contact

Sarah Hecker, Prevent Blindness, 312.363.6035, shecker@preventblindness.org

Twitter

SOURCE Prevent Blindness

Excerpt from:
May is Ultraviolet Awareness (UV) Month at Prevent Blindness, Designed to Educate the Public on the Best Ways to Keep Eyes Safe from UV Damage -...

ANN ARBOR, MI -Irreversible blindness affects at least 11 million Americans and 170 million across the world, according Michigan Medicine officials.

One of the leading factors of this condition is a disease called age-related macular degeneration, and an $11.5-million gift to the health system seeks to make the irreversible reversible.

The philanthropy from James Grosfeld, former chairman and CEO of PulteGroup Inc., goes toward research at the University of Michigan Kellogg Eye Center to develop effective treatments for the dry version of AMD, which affects up to 90% of those affected, officials said.

Grosfelds gift will support two endowed professorships at UM dedicated to dry AMD research, as well as increased laboratory staff. Other funded items include:

Increasing the speed and the breadth of discovery in dry AMD can make a significant difference in peoples lives, Grosfeld said in a statement.

Grosfelds enthusiasm and generosity has been greatly appreciated, said Dr. Paul Lee, director of the Kellogg Eye Center. The AMD research initiative will be led by Dr. Jason Miller, who will assume the title of the Grosfeld Professor of Ophthalmology and Visual Sciences.

We have made several discoveries that have given us a clear direction toward potential treatments, Miller said in a statement. At the same time, we have been building partnerships that will both accelerate our work and enable us to translate our efforts into clinical applications.

The AMD disease specifically attacks the part of the eye that houses the retinas light-sensitive photoreceptors. Millers research addresses how to limit the accumulation of lipids that affect these areas of the eye.

In catalyzing work across disciplines, we are enabling the creative application of a wide range of scientific techniques and approaches to the challenges of dry AMD, Dr. Marschall S. Runge, CEO of Michigan Medicine, said. Mr. Grosfelds visionary support will enable us to make important advances toward saving sight today and will create a legacy of sight-saving achievement.

Read more from The Ann Arbor News:

NBA All-Star Steve Smith to speak at Michigan States commencement

These are 10 historic buildings still standing on the University of Michigan campus today

Innovative allergy testing device earns University of Michigan student $25K

Read this article:
An end to blindness? $11M gift to Michigan Medicine researches eye treatments - MLive.com

Dynamic Culturing Process Developed by Lineage Offers Path to Clinical- and Industrial-Scale Production of Photoreceptors

CARLSBAD, Calif., April 25, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage. Similar to the companys recently announced pipeline expansion into auditory neurons for the treatment of hearing loss, Lineage has filed for intellectual property protection covering the composition and methods for generating PNCs. Based on recent in vivo data generated using the companys PNCs, these cells may be capable of forming reconstructed retina with high survivability and neural connectivity to surrounding functional layers. Notably, Lineage has demonstrated feasibility which could support a large-scale method for producing both types of photoreceptors, known as rods and cones.

"It is natural that, on the heels of the announcement of our alliance with Roche and Genentech for our RPE cell therapy, a deal worth up to $670 million dollars plus double-digit royalties if certain development, approval, and sales milestones are achieved and other conditions are met, that we also would pursue treatments for vision loss through the other major cell type of the retina, the photoreceptors," stated Brian Culley, Lineages CEO. "Our fundamental technology and accumulated know-how give us the opportunity to make many different cell types, and we have demonstrated our ability to create new programs rapidly and efficiently in two distinct areas, expanding our cell therapy pipeline to five separate preclinical and clinical programs, while still maintaining what we believe is an appropriate and responsible rate of investment for a company of our size. This latest program is part of our long-term planning for clinical and commercial success and serves as another example of the capability of our technology platform. We believe our ability to, in just a matter of months, advance from a product concept to generating new intellectual property and manufacturing the desired cell types, is illustrative of the power and efficiency of our platform. We believe the combination of our capital discipline and current balance sheet will support multiple years of further progress, during which we anticipate reaching achievements with each of our clinical and preclinical programs."

Story continues

Dr. Rami Skaliter, who leads the manufacturing function for Lineage, added, "Im exceptionally proud of the teams success at overcoming obstacles related to the limited scale of photoreceptor production. Building upon our experience with other cell lineages, we have developed intellectual property, and filed for patent protections, on a manufacturing process which is compatible with large-scale production of photoreceptors in a closed system, improvements which could enable industrial manufacturing. We believe this accomplishment will provide new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need such as Retinitis Pigmentosa, Stargardts Macular Dystrophy, and retinal detachments, either independently or through strategic alliances."

As part of a scientific collaboration with Professors Benjamin Reubinoff, M.D., Ph.D. and Eyal Banin, M.D., Ph.D., of the Hadassah-Hebrew University Medical Center, the differentiation of pluripotent cells into photoreceptors with clinically compatible characteristics was established utilizing a novel differentiation protocol which generated positive identity of key markers of both rods and cones photoreceptor populations. The data generated by the company further demonstrated that a single cell suspension of photoreceptor precursor cells has the potential to survive and mature post-transplantation in a rodent model of retinal degeneration.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include five allogeneic ("off-the-shelf") product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit http://www.lineagecell.com or follow the company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "aim," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "can," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to (i) the potential amount of payments to Lineage under the alliance with Hoffman-La Roche Ltd. ("Roche") and Genentech, Inc., (ii) the potential for new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need, (iii) Lineages position to become a leader in the emerging field of regenerative medicine and anti-aging technology, and (iv) future areas of potential treatment using PNC transplant. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the payments payable to Lineage under the Roche/Genentech collaboration and license agreement, the risk that Roche/Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; the risk that Lineage might not succeed in developing products and technologies that are useful in medicine and demonstrate the requisite safety and efficacy to achieve regulatory approval in accordance with its projected timing, or at all; the risk that Lineages intellectual property may be insufficient to protect its assets; risks and uncertainties inherent in Lineages business and other risks discussed in Lineages filings with the Securities and Exchange Commission (SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineages periodic reports with the SEC, including Lineages most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005336/en/

Contacts

Lineage Cell Therapeutics, Inc. IR Ioana C. Hone(ir@lineagecell.com)(442) 287-8963

Solebury Trout IR Mike Biega(Mbiega@soleburytrout.com)(617) 221-9660

Russo Partners Media Relations Nic Johnson or David SchullNic.johnson@russopartnersllc.com David.schull@russopartnersllc.com (212) 845-4242

Here is the original post:
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness - Yahoo...

The Russian invasion of Ukraine appears, on the surface, to be a land war. Newspapers lead with photographs of burned-out tanks, and on television and online we hear about the Belorussian border and truck convoys and listen to the expert commentary of generals. But this is a naval war as well.

Fighting has taken place both around the inland capitol of Kyiv, but also on the coast and over control of key port cities. While Russian explanation for new drive in the east focuses on the Russian-speaking population and territorial expansion, there is also a second and more strategic reason: the desire for a land bridge to Crimea, which would reduce the vulnerability of the Russian naval base at Sevastopol. When examining the maritime elements of the war, three points of analysis are worth consideration: first, the nature of conflict at sea and its existence out of sight of land and in a different domain which confounds our understanding; second, how the Russian navy pursued the basic elements of naval strategy reflects their continued relevance in this century; and third, the ways in which Ukraine has adapted to the conflict, and how it might make future adjustments, requires understanding of the naval past and creative thinking about the naval future.

Sea Blindness in Theory and in Practice

Over a decade ago, Butch Brakenel and James Kraska wrote that the United States suffers from a kind of sea blindness an inability to appreciate the central role the oceans and naval power have played in securing our strategic security and economic prosperity. Most use of sea blindness has tended to be metaphorical or focused on the grand economic and security connections between nations and the sea. Yet, in the Russo-Ukrainian war, the United States is experiencing sea blindness in a literal sense.

As various observers scroll through social media in search of open-source intelligence on the war, we are presented with a wealth of information that we then assess for validity and usefulness. However, very little of it is focused on the seas. Photos of burned-out T-72 tanks and trucks, video clips from targeting drones, or after-action threads that summarize changes in the fighting fill our feeds. For the most part, those of us who rely on open sources are blind to what is happening on the Ukrainian coast and in the Black Sea. The exceptions, like the final stand on Snake Island or the sinking of a Russian Alligator-class LST at the pier in Berdyansk, prove the rule. The early reports of the events surrounding the sinking of the cruiser Moskva illustrate this point also. These were based on the reposting of dueling press releases or online press reports rather than imagery, video, or on-scene information, which did not start to come until well after the fact.

A handful of media outlets and online trackers are trying to keep up with the maritime war. H.I. Sutton has been keeping the Covert Shores maritime open-source intelligence outlet going with information and writes reports for USNI News when they can confirm details. But an accurate picture of what is happening at sea is difficult. Truly actionable intelligence requires more than an occasional commercial satellite image or screenshots of maritime transponders. They involve electronic intercepts, radar, sonar, and elaborate collation and analysis efforts. All of these realities mean that while the NATO navies and Russian navy are actively producing their own maritime awareness, most of the rest of us are left in the dark about the conflict at sea.

But the fact that our Twitter feeds and Instagram scrolls are not filled with naval or maritime news does not mean that nothing is happening. It is important to remember that any war which takes place in a coastal territory (and many which take place in landlocked territory) have naval elements. The Russian invasion and Ukrainian defense of their sovereignty are no different, regardless of our sea blindness.

Retrospect: Naval Strategy in Action

As Bernard Brodie reminded us, boiled down to its simplest ideas, naval strategy can be described in a clear way. It begins with the need to establish command of the sea. It is taken further by determining what to do with the control that command of the sea offers.

Establishing command of the sea does not have to be global or even regional, but could simply be local to the area of operations. There tend to be two main ways to establish command. The first is to defeat the opponents navy or main battle fleet. By sinking the enemy, you keep them from being able to stop your use of the sea. But theres a second way to establish command, and that is to keep your opponents navy from ever putting to sea. Whether through blockade or by conducting strikes that sink them or limit their mobility while still in port, this can be equally effective.

Using the control created when you gain command of the sea is generally done in three ways. These operations are what I have previously called the 3 Bs of naval strategy: blockade, bombardment, or putting boots on the ground via amphibious landing. Naval strategy is the mixing and matching of these operations to achieve the political ends which are the purpose of the war. This effort to establish command of the sea, and then to use it, can offer us a good way to look at Russian naval operations in the first phase of the current war.

From the earliest days of the Russian invasion, the Russian navy has largely followed a classical strategy. When Russia annexed Crimea in 2014 and retook complete control of the then divided naval base at Sevastopol, where they leased facilities from Ukraine. It also took possession of nearly three quarters of the Ukrainian navy. When the Russian invasion began earlier this year, there was little more than a mosquito fleet of patrol boats to stand in their way. Russian naval forces out of Sevastopol include missile corvettes and frigates as well as some Kilo-class submarines, joined by the old Slava-class cruiser Moskva as the flagship. These were reinforced by amphibious ships from the Baltic Fleet and Northern Fleets before the invasion began. These ships largely bottled up the smaller Ukrainian patrol forces in port at the start of the war and established command of sea via blockade and strikes on Ukraines ports.

Russians quickly created a blockade of Ukraine by closing the Kerch Strait, which connects the smaller Sea of Azov to the Black Sea and established complete control of the Sea of Azov, and stationing ships off Odessa and other Ukrainian ports. The blockade remains unannounced, and therefore legally unofficial, but is in force with a de facto status. This status quo has remained unchallenged, though the wider maritime community has pointed out the negative effects on trapped neutral vessels and ships that have come under fire in the Black Sea. The resulting commercial blockade has ensured that Ukraine is cut off from the economic lifelines necessary to support its war, making the country entirely reliant on direct financial support from the West. Secondly, it eliminated the ability to resupply the Ukrainian military via the sea, which could have moved far more material far more quickly toward the fighting in the east than trucking it from the Polish border across the entire length of the country.

With total control of the Sea of Azov and the blockade holding, the Russian navy launched its first amphibious landings as a part of the offensive against Mariupol. Russian naval doctrine is designed to avoid contested amphibious landings, instead looking for a safe place to insert troops and equipment. This landing was no different, occurring approximately 30 miles southwest of the port city, away from defenders and closer to the safety of the Crimean Peninsula.

Amphibious assaults, landings made in the face of enemy defenses, are enormously difficult. The small craft used to connect amphibious ships to the shore, as well as amphibious ships like tank landing ships which can steam right up onto the beach, are enormously vulnerable to the kinds of light anti-tank weapons which have become ubiquitous in the Ukrainian defenses. Additionally, Russian amphibious forces are designed around surface landings and do not involve vertical envelopment doctrine with helicopters like many western naval services. With these limitations in mind, Russians began making pier-side reinforcement of their ground forces until the Ukrainians sank the Alligator-class amphibious ship Saratov while she was offloading at a pier in Berdyansk. The results of this attack may have made the Russians more cautious about these kinds of amphibious reinforcements, though the Pentagon spokesman has suggested resupply via sea continues.

Mariupol represents two elements that made it a key maritime target for the Russians. First, it is a significant port on the Sea of Azov and controlling it would continue to solidify that sea as a Russian lake. Second, control of Mariupol is vital to establishing a land bridge between Russian territory and the island of Crimea which is surrounded by Ukrainian territory. The Sevastopol naval base, which has been fought over for centuries as the key to the northern Black Sea, remains vulnerable so long as it is cut off from Russia itself. Annexing not only the Crimean Peninsula, but also the territory that connects it with the rest of Russia, is a classical naval mission since it secures the safety of Sevastopol.

In addition to the blockade and putting boots on the ground, from the earliest days of the invasion, Kaliber land-attack cruise missiles launched from Black Sea Fleet were a part of the bombardment. With over a thousand missiles launched into Ukraine by Russian forces it is safe to say that several hundred of those were naval strike missions, particularly around Odessa and coastal targets. Questions remain about Russian magazines of the missiles, and their ability to reload them. The loss of the Moskva, armed entirely with anti-ship and anti-air missiles, is far less significant in this regard than the Turkish closing of the Bosporus to warships, which keeps the Russians from reinforcing their fleet.

The establishment of command of the sea was followed rapidly by using the Sea of Azov and the Black Sea for operations affecting events ashore. The Sea of Azov was closed off and Ukrainian ports were blockaded, sealing off both military and commercial traffic. The Russian navy used the Sea of Azov to reinforce operations ashore and contributed to the brutal and ongoing assault on Mariupol. And the Black Sea Fleet fired hundreds of missiles in a wide-ranging bombardment that contributed to both tactical effects but also the indiscriminate destruction of civilian targets. Regardless of the legitimacy of the Russian aggression, the legality of the maritime operations, and clear movement toward war crimes, through the lens of naval strategy and in dramatic comparison to the failures of the Russian army, the Russian navy did its job effectively.

Prospect: Sea Denial and Contesting Command of the Sea

And yet, the relative success of the Russians at sea does not mean that their naval strategy is complete. Strategy is an activity that never ends. The realities of war, the contingency of human interactions, and the shifting context of conflict in an international space, all mean that the successful execution of a navys strategy can shift rudder in an instant. More often than not, that comes from a change in the enemys approach.

The trouble with command of the sea is that while it ideally would be complete and at the very least regionally enforceable, it is never totally achieved. Alfred Thayer Mahan and Julian Corbett were clear on this in their writing. They explained that while navies and naval strategists were right to aspire to a complete or total establishment of a general command of the sea, it would almost never happen in reality. In the particular case of a coastal nation fighting an expeditionary navy on its own shores, a country like Ukraine does not need to establish command of the sea for itself, it only needs to deny it to the enemy.

Despite his reputation for being focused exclusively on battleships and the battle fleet, a caricature of his actual naval writing, Mahan wrote extensively on the need for solid coastal defense as a joint army and navy mission as a part of any nations naval strategy. He broke coastal defense down into three key capabilities: shore-based gunnery, the use of mines, and small attack craft which meant torpedo boats at the dawn of the 20th century. As Jason Lancaster has written elsewhere, our modern versions of these remain available avenues of operations for Ukrainian forces as the Russian invasion shifts phases.

Today, coastal defense gunnery comes in many forms. The most obvious modern version of what used to be heavy artillery guns built into coastal fortifications are coastal defense cruise-missile systems. Rather than fixed weapons built into the stone or concrete of a coastal fort, they are often mobile and tied into a network of targeting data from radars and manned and unmanned intelligence collection systems. On April 13, 2022, Ukrainian forces reported their first successful cruise missile attacks on the Moskva. Details are unconfirmed, but we do know that the ship sank hours later while being towed to Sevastopol. While the Ukraine has a limited number of the indigenously produced Neptune missile systems, the United Kingdom has promised coastal defense cruise missiles as part of their most recent aid package. And cruise missiles are not the only weapons available for taking enemy ships under fire. The Bayraktar drones which have been used successfully against Russian armor also exist in a maritime version used by the Ukrainian navy and represent a capability that can be used against Russian warships. Additionally, munitions like the American Switchblade drones and laser-guided mortars have a more limited range but could be useful in the near littoral.

Mine warfare remains available to the Ukrainian navy as well. It is unclear to what extent it may have been used already to close off Russian operations close to shore. Russians have claimed that Ukrainians are using mines, and some have been found drifting in the Black Sea. Yet the source of those weapons is unclear, and the Russians could be using mines themselves to enhance their blockade, keeping ships from leaving port just as easily as they keep ships from entering. Mine warfare is a double-edged sword, because mining your own waters will require you to sweep them back up to make your harbors safe for commerce again, or to make them safe for resupply via sea. Ukraine may elect to use sea mines, but will likely do so in specific ways and in particular maritime geography where they are more likely to help than hurt.

Finally, coastal defense small craft remain an open question for Ukraine. The patrol vessels in its navy have already been targeted by the Russians, sinking the Solviansk in the first week of March. However, when it comes to small craft, the conversion of civilian vessels to military purposes is far easier than with medium to larger vessels. While it would likely be too difficult to mount British-supplied Harpoon missiles on small craft, the mortar tubes used to launch Switchblade drones and laser-guided mortars would be rather easy to bolt onto the aft deck of a civilian fishing or pleasure craft repurposed as naval raiders. Additionally, a recent list of new security assistance assets from the U.S. government includes Unmanned Coastal Defense Vessels. What these vessels look like, or their capabilities, are not clear since the U.S. Navy does not actively deploy anything that fits that description. It appears that the sinking of the Moskva has caused Russian warships to push themselves further offshore in order to avoid missile attacks. This transitions what had been a relatively close blockade to a far blockade and potentially opens up the seas for Ukrainian small craft to begin operating.

Naval Warfare in the Black Sea

In the first phase of the Russian war on Ukraine, the Russian navy largely succeeded in the basics of establishing a coherent naval strategy. It quickly established command of the sea by keeping Ukrainian ships from sailing. Once control of the waters of the southern coast of Ukraine and the Sea of Azov was established, the Russians began using it for their military purposes by blockading the coast, launching naval bombardments of targets both on the coast and well inland, and by landing boots on the ground with amphibious reinforcements of existing operations. Attempts to resupply Russian forces via the sea have been a mixed bag, with some success and some spectacular failures like the sinking of a Russian amphibious ship pier-side at Berdyansk. But the war on shore has entered a second phase. As Ukraine begins amassing more sophisticated and capable weapons, Russian forces face limitations due to the limited Turkish closure of the Bosporus under the terms of the Montreux Convention. The war at sea can shift as well.

The adoption of the classical methods of coastal defense, through the use of coastal gunnery and strike capabilities, careful employment of mine warfare, and adopting a creative approach to small craft, might allow Ukrainian forces to challenge Russian command of the sea. While they do not need to gain command for themselves, the ability to deny Russia easy and open use of the Black Sea and Sea of Azov could provide Kyiv with major benefits. The stunning sinking of the Moskva may be the turning point: As the Russian warships pull back from the coast to better protect themselves, they open more littoral maneuver space for Ukrainian forces. The adoption of greater coastal defense measures, combined with a limited guerre de razzia strategy that might even put the facilities as Sevastopol at risk, offers a clear naval strategy that will both limit the advantages the Russians established in the early weeks of the war while at the same time giving Ukrainian naval forces the opportunity to impose costs on Russian forces.

BJ Armstrong is a contributing editor with War on the Rocks and is the principal associate of the Forum on Integrated Naval History and Seapower Studies. His fourth book, Developing the Naval Mind, coauthored with John Freymann, was published in November. Opinions expressed in his article are offered in his personal and academic capacity, and do not reflect the positions or policies of the U.S. Naval Academy, the Department of Defense, or any other agency.

Image: Government of Ukraine

Visit link:
The Russo-Ukrainian War at Sea: Retrospect and Prospect - War on the Rocks

Museum guests who are red-green colour blind can now borrow special EnChroma glasses from the Chau Chak Wing Museum and experience exhibitions for example the vast array of blue hues in theCoastlines exhibition in clear, vibrant colour for the first time.

The accessibility of art and design is always top of mind at the Chau Chak Wing Museum and we are very pleased to be the first venue in Australia to offer this technology through EnChromas Colour Accessibility Program, said DrPaul Donnelly, Deputy Director of the Museum.

This partnership is another important step forward in our inclusivity goals, helping people who are colour blind to experience the full wonder and vibrancy of the exhibitions we have on offer.

One in 12 men (8 percent) and one in 200 women (0.5 percent) arecolour vision deficient; an estimated 350 million people worldwide.More than one million Australians are colour blind, as are over 3,500 of the 83,000 students and staff at the University of Sydney.

While people with normal colour vision see overone million shades of colour, those with colour visiondeficiencyonly see an estimated 10 percent of hues and shades.As a result, colours can appear dull, indistinct, and difficult to discern.

Go here to see the original:
Glasses bring colour to the museum - University of Sydney

life-style,

As they age, animals can experience a decline in their eyesight, but occasionally, some animals lose their vision altogether. This can be particularly distressing for the animal and owner if it occurs suddenly, as animals do not have time to adapt. Sudden, total vision loss is not typical of ageing and often indicates underlying disease that needs treatment. Animals that become blind suddenly may exhibit obvious behavioural changes, and appear disoriented. There are many causes of blindness. These include diseases that affect the surface of the eye (like dry-eye), the front chamber of the eye (like cataracts), the retina (like glaucoma or retinal detachment), the optic nerves (like infection or inflammation), and those impacting the brain (like stroke or organ failure). Blindness can also occur secondary to ingestion of toxins (for example, an overdose of ivermectin) or certain cancers (particularly eye and brain tumours). Some conditions, such as diabetes, predispose animals to developing cataracts. If you suspect that your pet has gone blind, it is important to seek veterinary attention as soon as possible. It is useful for your veterinarian to know whether you have observed a change in the appearance of the eyes, any changes in the overall health of your pet, and any recent medications they have been on, as well as any changes you have noted in their behaviour. Your veterinarian will conduct a physical examination and may perform additional tests, such as blood tests and blood pressure measurement. Your pet may be referred to a veterinary ophthalmologist for further evaluation and treatment. In some cases, blindness can be reversed with treatment. For example, it is possible for detached retinas to be surgically reattached. Similarly, cataracts may be removed. My late dog Phil was almost entirely blind when cataract surgery restored his vision. Interestingly, the first thing he did with his brand new eyes was walk up to the cat's food bowl and pee in it, as if he had been waiting for the opportunity to do so for some time. Because some conditions must be treated in a narrow window of time to ensure vision can be restored, it is important to see your veterinarian early if you suspect that your pet's vision has deteriorated. Dogs and cats can adapt well to loss of vision over time, with most able to successfully navigate their way around their home. If you do live with a blind or vision-impaired dog or cat, there are a number of steps that you can take to make life easier for them: REFERENCE BIONDI, V., PUGLIESE, M., VOSLAROVA, E., LANDI, A. & PASSANTINO, A. 2022. Animal Welfare Considerations and Ethical Dilemmas Inherent in the Euthanasia of Blind Canine Patients. Animals, 12. DOI: 10.3390/ani12070913 Dr Anne Quain BVSc (Hons), MANZCVS (Animal Welfare), Dip ECAWBM (AWSEL) is a lecturer at the Sydney School of Veterinary Science and a practising veterinarian.

/images/transform/v1/crop/frm/32UQzXcwHuv6EtT6StXJwQK/f5cdfb26-d7bf-421e-a6ef-6b0d68dd2bc5.jpg/r12_0_5108_2879_w1200_h678_fmax.jpg

As they age, animals can experience a decline in their eyesight, but occasionally, some animals lose their vision altogether.

This can be particularly distressing for the animal and owner if it occurs suddenly, as animals do not have time to adapt.

Sudden, total vision loss is not typical of ageing and often indicates underlying disease that needs treatment.

Animals that become blind suddenly may exhibit obvious behavioural changes, and appear disoriented.

There are many causes of blindness.

These include diseases that affect the surface of the eye (like dry-eye), the front chamber of the eye (like cataracts), the retina (like glaucoma or retinal detachment), the optic nerves (like infection or inflammation), and those impacting the brain (like stroke or organ failure).

Blindness can also occur secondary to ingestion of toxins (for example, an overdose of ivermectin) or certain cancers (particularly eye and brain tumours).

Some conditions, such as diabetes, predispose animals to developing cataracts.

If you suspect that your pet has gone blind, it is important to seek veterinary attention as soon as possible.

It is useful for your veterinarian to know whether you have observed a change in the appearance of the eyes, any changes in the overall health of your pet, and any recent medications they have been on, as well as any changes you have noted in their behaviour.

Your veterinarian will conduct a physical examination and may perform additional tests, such as blood tests and blood pressure measurement.

Your pet may be referred to a veterinary ophthalmologist for further evaluation and treatment.

In some cases, blindness can be reversed with treatment.

For example, it is possible for detached retinas to be surgically reattached. Similarly, cataracts may be removed.

My late dog Phil was almost entirely blind when cataract surgery restored his vision.

Interestingly, the first thing he did with his brand new eyes was walk up to the cat's food bowl and pee in it, as if he had been waiting for the opportunity to do so for some time.

Because some conditions must be treated in a narrow window of time to ensure vision can be restored, it is important to see your veterinarian early if you suspect that your pet's vision has deteriorated.

Dogs and cats can adapt well to loss of vision over time, with most able to successfully navigate their way around their home.

If you do live with a blind or vision-impaired dog or cat, there are a number of steps that you can take to make life easier for them:

BIONDI, V., PUGLIESE, M., VOSLAROVA, E., LANDI, A. & PASSANTINO, A. 2022. Animal Welfare Considerations and Ethical Dilemmas Inherent in the Euthanasia of Blind Canine Patients. Animals, 12. DOI: 10.3390/ani12070913

Dr Anne Quain BVSc (Hons), MANZCVS (Animal Welfare), Dip ECAWBM (AWSEL)is a lecturer at the Sydney School of Veterinary Science and a practising veterinarian.

More:
Lifting the lid on eye health and sight loss in your pets - Daily Liberal

Equities analysts expect LianBio (NASDAQ:LIAN Get Rating) to announce earnings per share (EPS) of ($0.26) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for LianBios earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.31). The firm is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that LianBio will report full-year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.07). For the next year, analysts expect that the business will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.20) to ($1.44). Zacks Investment Researchs EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for LianBio.

LianBio (NASDAQ:LIAN Get Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts consensus estimates of ($0.72) by $0.44.

Several institutional investors have recently modified their holdings of LIAN. Victory Capital Management Inc. acquired a new stake in LianBio during the 4th quarter worth $1,069,000. Bank of America Corp DE acquired a new stake in LianBio during the 4th quarter worth $519,000. Alps Advisors Inc. acquired a new stake in LianBio during the 4th quarter worth $750,000. Element Capital Management LLC acquired a new stake in LianBio during the 4th quarter worth $124,000. Finally, TD Asset Management Inc. acquired a new position in shares of LianBio in the 4th quarter valued at $954,000. 62.99% of the stock is owned by institutional investors and hedge funds.

Shares of LianBio stock traded down $0.26 during midday trading on Thursday, reaching $4.91. The company had a trading volume of 435,320 shares, compared to its average volume of 411,834. The companys fifty day moving average is $4.19. LianBio has a 1-year low of $2.61 and a 1-year high of $16.37.

About LianBio (Get Rating)

Lianbio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor IO combinations; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric and other cancers; BBP-398 for solid tumors; Omilancor for ulcerative and Crohn's disease; NH-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

Recommended Stories

Get a free copy of the Zacks research report on LianBio (LIAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.

See more here:
LianBio (NASDAQ:LIAN) Expected to Post Earnings of -$0.26 Per Share - Defense World

Scientists from the United Kingdom have analyzed the full genetic blueprints of more than 18,000 cancer samples, finding new patterns of mutations that could help doctors provide better, more personalized treatment

By LAURA UNGAR AP Science Writer

April 21, 2022, 6:02 PM

3 min read

Scientists have analyzed the full genetic blueprints of more than 18,000 cancer samples, finding new patterns of mutations that could help doctors provide better, more personalized treatment.

Their study, published Thursday in the journal Science, isnt the first to do such comprehensive whole genome analyses of cancer samples. But no one has ever done so many.

This is the largest cohort in the world. It is extraordinary, said Serena Nik-Zainal of the University of Cambridge, who was part of the team.

Just over 12,200 surgical specimens came from patients recruited from the U.K. National Health Service as part of a project to study whole genomes from people with common cancers and rare diseases. The rest came from existing cancer data sets.

Researchers were able to analyze such a large number because of the same improvements in genetic sequencing technology that recently allowed scientists to finally finish decoding the entire human genome more capable, accurate machines.

We can really begin to tease out the underpinnings of the erosive sort of forces that go to sort of generate cancer," said Andrew Futreal, a genomic medicine expert at MD Anderson Cancer Center in Houston who was not involved in the study.

Cancer is a disease of the genome, or full set of instructions for running cells, that occurs when changes in a persons DNA cause cells to grow and divide uncontrollably. In 2020, there were about 19 million new cancer cases worldwide.

For the study, researchers looked at 19 different types breast, colorectal, prostate, brain and others and identified 58 new clues to the causes of cancer called mutational signatures" that contribute to the development of the disease. They also confirmed 51 of more than 70 previously reported mutation patterns, Nik-Zainal said.

Some arise because of problems within a persons cells; others are sparked by environmental exposures such as ultraviolet radiation, tobacco smoke or chemicals.

Knowing more of them helps us to understand each persons cancer more precisely, which can help guide treatment, Nik-Zainal said.

Genetic sequencing is already being woven into cancer care as part of the growing trend of personalized medicine, or care based on a patients genes and specific disease. Now doctors will have much more information to draw from when they look at individual cancers.

To help doctors use this information, researchers developed a computer algorithm that will allow them to find common mutation patterns and seek out rare ones. Based on a particular pattern, Nik-Zainal said a doctor may suggest a certain course of action, such as getting immunotherapy.

Futreal said the data can also show doctors what tends to happen over time when a patient develops a cancer with a certain mutation pattern helping them intervene earlier and hopefully stop the developing disease in its tracks.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

Read the original post:
Study mines cancer genetics to help with targeted treatment - ABC News

Pregnancy for women marks the beginning of a new stage in their lives. Like any other parent, Juhi (namechanged) was excited when she learned about her pregnancy. She had suffered a miscarriage previouslyas her foetus was affected by down syndrome. While consulting with a geneticist, she was advised of a few options that included a non-invasive prenatal test (NIPT) to help screen for down syndrome and a fewother chromosomal disorders. She chose NIPT and waited anxiously for the results. The results arrived soon enough, and it was observed that Juhis baby had a very low or negligible risk ofhaving a serious chromosomal disorder. A few months later she delivered a healthy baby girl. Juhi was elated with the outcome and also understood the value of a genetic test and now advises all herrelatives to undergo a prenatal screening test. A non-invasive prenatal screening test provides expecting parents with reliable information about theirbabys genetic makeup. Such information is vital to expectant parents for thought-through earlypregnancy decisions and to avoid the distress caused by the birth of an abnormal baby unexpectedly.

What are chromosomaldisorders?

The human genetic material consists of 23 pairs of chromosomes. Therefore, any change in this number,wherein extra gain or loss of chromosome can lead to a serious disorder. The most common of thesedisorders are, Trisomy 21, Trisomy 18 and Trisomy 13, in the population.The estimated risk incidence of a baby with a chromosomal disorder is 1:166 births.Therefore, standard pregnancy care involves early screening for serious chromosomal abnormalities.

Genetic screening tests allow for identifying the genetic disorders or potential risks that the unborn babymay carry.NIPT (Non-Invasive Prenatal Test) has brought precision to the practice of diagnosis. With the advancement in technology, tests have been developed that are safe for the foetus and non-invasive. The non-invasive prenatal screening test can screen for common chromosomal abnormalitiessuch as Trisomy 21(Down syndrome), Trisomy 18 (Edward syndrome), Trisomy 13 (Patau syndrome) andcertain other abnormalities like monosomy X (Turners syndrome). There are three main reasons why couples should opt for a test:

It helps identify foetuses at risk of serious chromosomal abnormality.

Leads to better management by providing early information.

Prepares for birth and early intervention wherever possible.

Who needs to get tested?

Non-invasive prenatal testing can be recommended to any pregnant woman but is usually recommendedwhen:

The woman is above 30 years of age. Maternal serum screening provides abnormal results.

Certain abnormalities during the ultrasound are identified.

There is a family history of chromosomal conditions or congenital disabilities.

Couples have had a child with a chromosomal disorder.

A couple has a history of infertility or pregnancy loss.

Genetic testing of the pregnancy remains important as pregnancy is a time-sensitive period. When the general pregnant population is screened, most pregnancies eventually have a low risk of theseconditions. However, about 2-3% of the tested population by NIPT, receive a highrisk result whichrequires follow up confirmatory testing through invasive procedures.

(The author is an expert atreproductive genomics.)

See more here:
It's in the genetics - Deccan Herald

Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87108 (2015).

Article Google Scholar

Finnish Cancer Registry. Cancer Statistics Application (Finnish Cancer Registry, 2020).

Google Scholar

Nagy, R., Sweet, K. & Eng, C. Highly penetrant hereditary cancer syndromes. Oncogene 23(38), 64456470. https://doi.org/10.1038/sj.onc.1207714 (2004).

CAS Article PubMed Google Scholar

Wendt, C. & Margolin, S. Identifying breast cancer susceptibility genesA review of the genetic background in familial breast cancer. Acta Oncol. 58(2), 135146. https://doi.org/10.1080/0284186X.2018.1529428 (2019).

CAS Article PubMed Google Scholar

Melchor, L. & Bentez, J. The complex genetic landscape of familial breast cancer. Hum. Genet. 132(8), 845863. https://doi.org/10.1007/s00439-013-1299-y (2013).

CAS Article PubMed Google Scholar

Vahteristo, P., Eerola, H., Tamminen, A., Blomqvist, C. & Nevanlinna, H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br. J. Cancer 84(5), 704708 (2001).

CAS Article Google Scholar

Eerola, H., Aittomki, K. & Nevanlinna, H. Genetic susceptibility to breast cancer. Finnish Med. J. 46, 46954701 (2002).

Google Scholar

Li, J. et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int. J. Cancer 144(5), 11951204. https://doi.org/10.1002/ijc.31841 (2019).

CAS Article PubMed Google Scholar

Syrjkoski, K. et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J. Natl. Cancer Inst. 92(18), 15291531. https://doi.org/10.1093/jnci/92.18.1529 (2000).

Article PubMed Google Scholar

Buys, S. S. et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123(10), 17211730. https://doi.org/10.1002/cncr.30498 (2017).

CAS Article PubMed Google Scholar

Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23), 24022416. https://doi.org/10.1001/jama.2017.7112 (2017).

CAS Article PubMed Google Scholar

Chen, S. & Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25(11), 13291333. https://doi.org/10.1200/JCO.2006.09.1066 (2007).

Article PubMed Google Scholar

Tai, Y. C., Domchek, S., Parmigiani, G. & Chen, S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 99(23), 18111814. https://doi.org/10.1093/jnci/djm203 (2007).

CAS Article PubMed Google Scholar

Mersch, J. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2), 269275. https://doi.org/10.1002/cncr.29041 (2015).

CAS Article PubMed Google Scholar

Rebbeck, T. R. et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13), 13471361. https://doi.org/10.1001/jama.2014.5985 (2015).

CAS Article PubMed PubMed Central Google Scholar

GeneReviews. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. https://www.ncbi.nlm.nih.gov/books/NBK1247/ (Accessed 20 June 2020).

Metcalfe, K. et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br. J. Cancer 121(1), 1521. https://doi.org/10.1038/s41416-019-0446-1 (2019).

Article PubMed PubMed Central Google Scholar

Tschernichovsky, R. & Goodman, A. Risk-reducing strategies for ovarian cancer in BRCA mutation carriers: A balancing act. Oncologist 22(4), 450459. https://doi.org/10.1634/theoncologist.2016-0444 (2017).

CAS Article PubMed PubMed Central Google Scholar

Terry, M., Daly, M. & Phillips, K. Y. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J. Natl. Cancer Inst. 111(3), 331334 (2019).

Article Google Scholar

Auranen, A. Perinnllisen sypalttiuden tunnistamisella on merkityst mys gynekologisten sypien ehkisyss. Duodecim 134, 12621264 (2018).

Google Scholar

Kotsopoulos, J. BRCA mutations and breast cancer prevention. Cancers (Basel) 10(12), 524. https://doi.org/10.3390/cancers10120524 (2018).

CAS Article Google Scholar

Li, X. et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Clin. Cancer Res. 22(15), 39713981. https://doi.org/10.1158/1078-0432.CCR-15-1465 (2016).

CAS Article PubMed Google Scholar

Pierce, L. J. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol. 24(16), 24372443. https://doi.org/10.1200/JCO.2005.02.7888 (2006).

Article PubMed Google Scholar

George, A., Kaye, S. & Banerjee, S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat. Rev. Clin. Oncol. 14(5), 284296. https://doi.org/10.1038/nrclinonc.2016.191 (2017).

CAS Article PubMed Google Scholar

Robson, M. E. et al. American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J. Clin. Oncol. 33(31), 36603667. https://doi.org/10.1200/JCO.2015.63.0996 (2015).

CAS Article PubMed Google Scholar

Manchanda, R., Sun, S. & Patel, S. Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health. Cancer 12(7), 1929. https://doi.org/10.3390/cancers12071929 (2020).

CAS Article Google Scholar

Yang, X. et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. J. Clin. Oncol. 38(7), 674685. https://doi.org/10.1200/JCO.19.01907 (2020).

CAS Article PubMed Google Scholar

Kankuri-Tammilehto, M., Vihinen, P. & Schleutker, J. Heredity of cancer. Finnish Med. J. 14, 880886 (2019).

Google Scholar

Kiiski, J. I. et al. FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. Breast Cancer Res. Treat. 166(1), 217226. https://doi.org/10.1007/s10549-017-4388-0 (2017).

CAS Article PubMed PubMed Central Google Scholar

Mavaddat, N., Antoniou, A. C., Easton, D. F. & Garcia-Closas, M. Genetic susceptibility to breast cancer. Mol. Oncol. 4(3), 174191. https://doi.org/10.1016/j.molonc.2010.04.011 (2010).

CAS Article PubMed PubMed Central Google Scholar

Barkardottir, R. et al. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur. J. Hum. Genet. 9(10), 773779 (2001).

CAS Article Google Scholar

Vehmanen, P. et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum. Mol. Genet. 6, 2309 (1997).

CAS Article Google Scholar

Huusko, P. et al. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am. J. Hum. Genet. 62, 1544 (1998).

CAS Article Google Scholar

Sarantaus, L. et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur. J. Hum. Genet. 8(10), 757763 (2000).

CAS Article Google Scholar

Thomassen, M. et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Actancology 47, 772777 (2008).

CAS Google Scholar

Moller, P. et al. Genetic epidemiology of BRCA mutationsFamily history detects less than 50% of the mutation carriers. Eur. J. Cancer 43, 17131717 (2007).

Article Google Scholar

Rebbeck, T. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 35, 593 (2018).

Article Google Scholar

Li, J. et al. Cancer therapy and prevention open access prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int. J. Cancer 144(5), 11951204 (2019).

CAS Article Google Scholar

Kremeyer, B. et al. The BRCA1 exon 13 duplication in the Swedish population. Fam. Cancer 4, 191194 (2005).

Article Google Scholar

Tonin, P. et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat. Med. 2, 11791183 (1996).

CAS Article Google Scholar

Iyevleva, A. G. et al. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett. 298, 258263 (2010).

CAS Article Google Scholar

Ghadirian, P. et al. The contribution of founder mutations to earlyonset breast cancer in French-Canadian women. Clin. Genet. 76, 421426 (2009).

CAS Article Google Scholar

Daly, M. B. et al. NCCN guidelines insights: Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017. J. Natl. Compr. Cancer Netw. 15(1), 920. https://doi.org/10.6004/jnccn.2017.0003 (2017).

CAS Article Google Scholar

Yang, X. et al. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. J. Med. Genet. 55(8), 546554. https://doi.org/10.1136/jmedgenet-2018-105313 (2018).

CAS Article PubMed Google Scholar

Mars, N. et al. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nat. Commun. 11(1), 6383. https://doi.org/10.1038/s41467-020-19966-5 (2020).

ADS CAS Article PubMed PubMed Central Google Scholar

Finnish Breast Cancer Group. Rintasyvn valtakunnallinen diagnostiikka- ja hoitosuositus 2019. (Accessed 20 June).

Phi, X. A. et al. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age 50 years: Evidence from an individual patient data meta-analysis. J. Clin. Oncol. 33(4), 349356. https://doi.org/10.1200/JCO.2014.56.6232 (2015).

Article PubMed Google Scholar

Paluch-Shimon, S. et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 27(suppl 5), 103110. https://doi.org/10.1093/annonc/mdw327 (2016).

Article Google Scholar

Boyle, P. Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann. Oncol. 23(Suppl 6), 712. https://doi.org/10.1093/annonc/mds187 (2012).

Article Google Scholar

Foulces, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 19381948. https://doi.org/10.1056/NEJMra1001389 (2010).

Article Google Scholar

Schaapveld, M. et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: A population based study in the Netherlands. Breast Cancer Res. Treat. 110(1), 189197. https://doi.org/10.1007/s10549-007-9709-2 (2008).

CAS Article PubMed Google Scholar

Originally posted here:
Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland | Scientific...

Breadcrumb Trail Links

If we understand the causes of cancer, then we can start highlighting the known causes, the lifestyle issues that introduce or increase our risk

Environmental and metabolic factors not just genetics are growing considerations in the fight against cancer, concludes a research review by a leading expert at the University of Alberta.

This advertisement has not loaded yet, but your article continues below.

Cancer as a genetic disease, focusing on the set of genetic instructions every person is born with; it is also an environmental disease, focusing on the exposome, which includes everything a persons body has been exposed to; and cancer is a metabolic disease, focusing on the metabolome, or all the chemical byproducts of the process of metabolism, explains David Wishart, professor in the departments of biological sciences and computing science, in a Thursday news release.

But that metabolic perspective hasnt had much research until now, as more scientists begin to understand the metabolomes role in cancer.

Heritable cancers account for just five to 10 per cent of all cancers, Wishart said, with the other 90 to 95 per cent initiated by factors in the exposome, which in turn trigger genetic mutations.

This advertisement has not loaded yet, but your article continues below.

Thats an important thing to consider, because it says that cancer isnt inevitable.

As cancer develops and spreads in the body, it creates its own environment and introduces certain metabolites, becoming a self-fuelled disease. And thats where cancer as a metabolic disorder becomes really important.

Considering the genome, exposome and metabolome together when thinking about cancer shows more promise for finding treatments.

Researchers who focus only on the genetic perspective are looking to address particular mutations but there are around 1,000 genes that can become cancerous when mutated, and it typically takes two different mutations within these cells for cancer to grow, notes Wishart, meaning there are a million potential mutation pairs. Then it can become hopeless to narrow down possibilities when seeking new treatments.

This advertisement has not loaded yet, but your article continues below.

But considering cancer from the metabolic perspective, there are just four major metabolic types, said Wishart, so determining the patients cancer type can immediately guide doctors on the best treatment for their specific cancer.

It really doesnt make a difference where the cancer is its something youve got to get rid of. Its how it thrives or grows that matters, said Wishart. It becomes a question of, Whats the fuel that powers this engine?

Wishart cautions that health-care providers still need a mix of therapeutics for cancer, and a deeper understanding of the metabolome and its role in the cancer feedback loop is also critical to preventing cancer.

If we understand the causes of cancer, then we can start highlighting the known causes, the lifestyle issues that introduce or increase our risk, he said.

From the prevention side, changing our metabolism through lifestyle adjustments will make a huge difference in the incidence of cancer.

The research review was funded by Genome Canada, the Canadian Institutes of Health Research and the Canada Foundation for Innovation.

This advertisement has not loaded yet, but your article continues below.

Sign up to receive daily headline news from the Edmonton Journal, a division of Postmedia Network Inc.

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Edmonton Journal Headline News will soon be in your inbox.

We encountered an issue signing you up. Please try again

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Continue reading here:
Treating, preventing cancer beyond genetics: U of A researcher - Edmonton Journal

Photo provided by Lionheart Cannabis

Chris Fanuzzi calls it his genetic library.

Seed descriptions, batch logistics and references to growers and cultivators who supplied some of the seeds are all noted in the heaps of pages of mostly handwritten notes in his trusty binder.

There are more than 400 recipes for Fanuzzis renowned rotating cannabis menu items, including the famous original Montana Silvertip, a hybrid strain. In the cannabis industry, the term strain refers to a variety of the cannabis plant and can include characteristics such as chemical profile, appearance and effects on consumers.

Maintaining the integrity of the original seeds over time is incredibly difficult for any cultivator, said Fanuzzi, owner and founder of Lionheart Cannabis, Montanas leading medical and recreational cannabis provider. Its an art to be able to sustain a particular genetic makeup of any one plant, especially when you consider these plants are growing alongside one another with the ability to pick up characteristics of the plant strains located, literally, right next to them. And that doesnt even take into account trying to maintain a completely stable environment from year to year, all against a backdrop of legislation that is constantly changing.

People are also reading

But Fanuzzi has made it work. His company is renowned for its focus on quality, top-of-the-line products, compassionate patient care and educational awareness among clients.

Lionheart currently produces myriad oils, edibles and tinctures in a variety of flavors, strengths and price ranges. In addition to its headquarters in Bozeman, the company has five cultivation facilities throughout the state, as well as dispensaries in Billings, Butte, Helena, Great Falls (Herbal Bliss), Kalispell, Livingston andMissoula.

With 50 to 60 strains on the shelves at any one time, Lionheart is set to roll out scrolling digital menus that will provide customers with real-time product availability and pricing. The company is also enhancing its on-site customer experience by redesigning retail space to include more open floor plans and visual product display areas.

We want to encourage our customers to spend as much time as they want with our budtenders when they are onsite, to look at every jar to find that bud that is really going to work for them, he said. The online menu will only complement that experience.

But back to Montana Silvertip. A genetic cross between Purple Urkel (also known as Granddaddy Purple) and Super Silver Haze, the sativa-dominant bud has a THC level anywhere from 20% to 30%, with an earthy pine and blueberry taste.

Its an absolutely beautiful strain with hues of bright lavender and frosty white, Fanuzzi said. We continue to cross-pollinate its seeds with some of our other renowned strains such as Wedding Crasher, Mandarin Cookie, Purple Punch and Meathead, resulting in some really incredibly viable genetics with lots of different properties that are very popular with our customers.

Other favored staff picks include Do Si Dos, Kimbo Kush, Blue Dream, Lucky Charms, Key Lime Pie and Ginger Tea. And while consumers should note the THC potency levels listed on the product packaging, Fanuzzi said other things to consider include terpene profiles, how the buds are stored (glass jars and turkey bags are best), the smell (too much moisture results in a moldy odor) and feel (should feel spongy like a marshmallow when squeezed). If the bud is too dry, it will crumble. Also, buds stored in sunlight lose their potency more quickly.

Fanuzzi said as his recipe library for strains continues to grow, it also includes notations for those strains that have been bred out over time, including one of his most legendary" strains, the Papaya. Unfortunately, I developed it back in 2007 and never cloned it. So once it was gone, it was gone, recalled Fanuzzi.

Strains today represent combinations and cross-breeding of some of the best products and varieties people like. There are only so many families of land-raised genetics out there, so you continue to fine-tune until you achieve what you think is the perfect combination.

At that point, Fanuzzi adds another page to his binder.

Visit lionheartcannabis.com for more information.

Information provided is for educational and informational purposes only and does not supersede any medical advice given by a physician. Cannabis is still considered a schedule 1 controlled substance and is illegal under federal law. Adults who consume cannabis must keep cannabis products away from animals and out of reach of children. Note that the intoxicating effects of cannabis can sometimes be delayed, so do not operate a vehicle or machinery after consumption. Use of cannabis during pregnancy or while breastfeeding may be harmful. By purchasing cannabis from a dispensary, you are assuming the risk of any damage or loss that occurs during its use.

Get local news delivered to your inbox!

See the original post:
Lionheart Cannabis' genetic strains stand the test of time - Billings Gazette

Is it possible to breed low-emissioncattle and sheep?

A group of Australian researchers and industry leaders think so and they are putting $19 million towards making it happen.

The University of New England, Armidale (UNE) is collaborating with Angus Australia, Meat and Livestock Australia and the NSW Department of Primary Industry to develop genetics to breed livestock that emits less methane.

The project is in line with the beef industry's goal to reach zero carbon emissions by 2030.

"We have always been keen to look at measuring the traits related to methane emissions on our cattle so in the future we can select Angus bulls that will produce lower methane but still be productive," Angus Australia's general manager for genetic improvementChristian Duffsaid.

Mr Duff said the organisation's involvement in the project was driven by the consumer.

"There is no doubt there is a trend towards people wanting to be aware of where their product comes from and its impact on the environment.

"The way we can have an impact is by making sure we're recording those methane traits on cattle ... and then in the future having information to select bulls."

UNE researchersare confident that, through the project, they can achieve a steady and permanent reduction in methane emissions from livestock.

Two UNEprofessors will investigate how to improve the genetic make-up of sheep and cattle.

Over the next five years, they will measure the methane output of 8,000 cattle and 10,000 sheep living in both feedlot and grazing conditions.

The variation between different animals will be analysed and data used to predict which of those animals have genetics that may lower the emissions they produce.

Associate Professor Sam Clark willresearchthe beef component, and saidboth projects could result in a 25 per cent reduction in methane emissions in livestock by 2050.

"A plausible amount to expect from genetic technologies is about 1 per cent methane reduction per year,"he said.

"The key point about that 1 per cent per year is that, when we use breeding to make that change, it's cumulative and permanent.

"It's a bit like your interest rate for the bank, it just keeps accumulating on top of itself."

The project is scheduled to start laterthis month.

See more here:
Armidale researchers hope genetic selection will be key to raising steaks with lower emissions - ABC News

About the position

There is a vacancy for one PhD candidate at The Department of Clinical and Molecular Medicine in collaboration with The Department of Medical Genetics at St. Olavs hospital. The PhD candidate will work on different aspects of the Clinical Academic Group for Rare Genetic Diseases (CAG).

One of the main aims of the CAG is to apply state-of-the-art disease-modelling to the rare genetic diseases. The PhD project will address the steps in onset of neurodevelopmental diseases and identify potential points for diagnostic and therapeutic intervention.

We have implemented different human cell culture and organoid models that enable studying of disease development and progression, as well as the analysis of relevant pathomechanisms. The PhD student will be involved in generation and characterization of patient-specific and healthy-individual induced pluripotent stem cells, development of disease models and their characterization through transcriptome and proteome analysis, imaging and functional testing. As such the project includes work with big data sets.

Required selection criteria

The appointment is to be made in accordance with the regulations in force concerningState Employees and Civil ServantsandRegulations concerning the degrees ofPhilosophiaeDoctor (PhD)andPhilosodophiaeDoctor (PhD) in artistic researchnational guidelines for appointment as PhD, post doctor and research assistant

Preferred selection criteria

Personal characteristics

We offer

Salary and conditions

PhD candidates are remunerated in code 1017, and are normally remunerated at gross from NOK 491 200 per annum before tax, depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The period of employment is 3 years.

Appointment to a PhD position requires that you are admitted to thePhD programme in Medicine and Health Sciences within three months of employment, and that you participate in an organized PhD programme during the employment period.

The engagement is to be made in accordance with the regulations in force concerning State Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

It is a prerequisite you can be present at and accessible to the institution daily.

About the application

The application and supporting documentation to be used as the basis for the assessment must be in English.

Publications and other scientific work must follow the application. Please note that applications are only evaluated based on the information available on the application deadline. You should ensure that your application shows clearly how your skills and experience meet the criteria which are set out above.

The application must include:

If all,or parts,of your education has been taken abroad, we also ask you to attach documentation of the scope and quality of your entire education, both bachelor's and master's education, in addition to other higher education. Description of the documentation required can befoundhere. If you already have a statement fromNOKUT,pleaseattachthisas well.

Joint works will be considered. If it is difficult to identify your contribution to joint works, you must attach a brief description of your participation.

In the evaluation of which candidate is best qualified, emphasis will be placed on education,experienceand personal and interpersonalqualities.Motivation,ambitions,and potential will also countin the assessment ofthe candidates.

NTNU is committed to following evaluation criteria for research quality according toThe San Francisco Declaration on Research Assessment - DORA.

General information

Working at NTNU

A good work environment is characterized by diversity. We encourage qualified candidates to apply, regardless of their gender, functional capacity or cultural background.

The city of Trondheimis a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

As an employeeatNTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

In accordance with The Public Information Act (Offentleglova), your name, age, position and municipality may be made public even if you have requested not to have your name entered on the list of applicants.

If you have any questions about the position, please contact Professor Barbara van Loon, telephone +47 73 59 84 23, emailbarbara.v.loon@ntnu.no; Senior consultant clinical geneticist Rune stern, emailRune.Ostern@stolav.no. If you have any questions about the recruitment process, please contact Vebjrn F. Andreassen, e-mail:vebjorn.andreassen@ntnu.no

Please submit your application electronically via jobbnorge.no with your CV, diplomas and certificates. Applications submitted elsewhere will not be considered. Diploma Supplement is required to attach for European Master Diplomas outside Norway. Chinese applicants are required to provide confirmation of Master Diploma fromChina Credentials Verification (CHSI).

Application deadline: 16.05.22

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

The Department of Clinical and Molecular Medicine (IKOM):

The Department of Clinical and Molecular Medicine (IKOM) is NTNUs largest department, with 450 employees. Our research and teaching help to improve treatment and health.

IKOM has expertise in basic, clinical and translational research within broad disciplinary areas. We study childrens and womens health, cancers, blood disorders and infectious diseases, gastroenterology, inflammation, metabolic disorders, laboratory sciences and medical ethics. The Department offers teaching in medicine at masters and PhD level. We also offer continuing education for employees in the health services.

Deadline16th May 2022EmployerNTNU - Norwegian University of Science and TechnologyMunicipalityTrondheimScopeFulltimeDurationProjectPlace of service

Excerpt from:
PhD Candidate in Rare Genetic Diseases job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 291220 - Times Higher Education

Daewoong Pharmaceutical and HanAll Biopharma invest in the broad potential of Turn Biotechnologies

Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases

SEOUL, South Korea, April 11, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (KRX: 069620.KS) and HanAll Biopharma (KRX: 009420.KS) today announced expansion of their open collaboration strategy by investing in Turn Biotechnologies, a Silicon Valley based company focused on developing novel mRNA medicines. The companies are supporting Turn Bio's continued development of a high-potential platform and are considering future long-term collaborations.

Turn Bio is a pre-clinical-stage biopharmaceutical company focused on cellular repair via epigenetic reprogramming of cells. The technological foundation for Turn Bio's proprietary Epigenetic Reprogramming of Age (ERA) methodology was developed by Turn Bio's co-founders in the Sebastiano Lab, Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine. The technology has since been patented and Turn Bio is currently using it to complete pre-clinical research on therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteoarthritis and the muscular system.

"Many age-related diseases have long been significant areas of patients' unmet need," said Dr. Almira Chabi, chief medical officer and chief development officer at HanAll Pharmaceutical International. "Turn Bio's innovative platform may bring a pivotal transformation to a wide array of therapeutic areas. HanAll is committing support and investment to help realize the full potential of this pioneering technology as Turn Bio advances to a new phase of growth."

"The support of Daewoong Pharmaceutical and HanAll Biopharma validates our approach to cellular rejuvenation and enables Turn to expand its efforts in multiple therapeutic indications," said Anja Krammer, the company's CEO. "We are thrilled that a company as well known for its innovation, has taken interest in our promise to transform the way medicine treats diseases of aging and we look forward to further collaborations to help change quality of life and healthcare economics globally."

Story continues

The proceeds from this round of financing will support Turn Bio's advancement towards a phase 1 trial of its mRNA therapy candidate TRN-001, which targets indications in dermatology.

About HanAll Biopharma Co., Ltd.

HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company founded in 1973, with a mission of making meaningful contributions to patients' lives by introducing innovative, impactful therapies to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for more than 48 years.

HanAll has also expanded its focus to ophthalmology, immunology, oncology and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. A leading pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody drug, is in Phase 3 and Phase 2 trials across the world for the treatment of rare autoimmune disorders including myasthenia gravis, thyroid eye disease, warm autoimmune hymolytic anemia, neuromyelitis optica, and immune thrombocytopenia. Another main asset, HL036 (INN: tanfanercept), an anti-TNF alpha protein drug, is in Phase 3 clinical trials in the US and China for the treatment of dry eye disease.

For further information visit our website, and connect with us on linkedin. For any media inquiries, please contact HanAll PR/IR (pr@hanall.com, ir@hanall.com).

About Daewoong Pharmaceutical. Co., Ltd. (https://www.daewoong.co.kr/en)

Established in 1945, Daewoong Pharmaceutical Co., Ltd. is a leading South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both domestic and international markets. With a strong and innovative in-house R&D and advanced manufacturing facilities, Daewoong provides a total healthcare solution to customers across the globe. Continuing on its course of building a strong global healthcare company, Daewoong has broadened international operations by establishing branch offices and research centers throughout Asia and the United States. Daewoong has also expanded strategic partnerships in more than 100 countries worldwide.

About Turn Biotechnologies

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company's proprietary mRNA platform technology, ERA, restores optimal gene expression by combatting the effects of aging in the epigenome. This restores the cells' ability to prevent or treat disease, and heal or regenerate tissue and will help to fight incurable chronic diseases.

Turn Bio's technology provides a platform from which to attack a variety of now incurable chronic diseases. The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see turn.bio or contact Jim Martinez, rightstorygroup / jim@rightstorygroup.com or (312) 543-9026.

Disclaimer statement

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements HANALL (the company, we) makes concerning its 2022 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results of its strategy and the company, and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors our expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; our reliance on collaborations with third parties; estimating the commercial potential of our product candidates; our ability to obtain and maintain protection of intellectual property for its technologies and drugs; our limited operating history; and our ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in Korea Stock Exchange (KRX) filings and reports, including in our most recent annual report as well as subsequent filings and reports filed by the company with the KRX. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. We undertake no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by Korean law and regulations.

Cision

View original content:https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-and-hanall-biopharma-invest-in-turn-biotechnologies-to-expand-growth-initiative-301522583.html

SOURCE Daewoong Pharmaceutical and HanAll Biopharma

Follow this link:

Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative - Yahoo Finance

Andrea Williams, chief executive of Christian Concern, said: Whatever is announced by the Government in May, the problems remain: the definitions are inadequate, human rights will be breached and there is no evidence that a ban will help anyone.

In such a scenario we will face no alternative but to pursue legal action against any proposed legislation in this area.

Ms Williams added: The Government is being strong-armed by manipulative campaigns rather than following its own research that further legislation is not needed.

The fear of upsetting privileged lobbyists runs so deep the Prime Minister capitulated within hours.

No one has produced any evidence of what LGBT activists call coercive conversion therapy. What the activists describe would already be illegal.

The Governments proposals would only stop people seeking the change they want to see in their lives. That is a basic freedom which the Government should not try to take away.

Last week the Government was forced to cancel its first ever LGBT+ conference after more than 100 activist groups quit over its U-turn on conversion therapy.

As a result of the Government reiterating its commitment to excluding transgender people from the conversion therapy ban, a number of leading charities and organisations pulled out of the inaugural and international event, called Safe To Be Me.

It was set to take place in London from June 29 to July 1, coinciding with the 50th anniversary of the first official London Pride marches.

Christian Concern has threatened, if the Government does go ahead with any of its proposals as part of the Queens Speech on May 10, to bring legal proceedings on grounds of infringement upon rights of religious freedom enshrined in the European Convention on Human Rights.

A spokesman for Stonewall, one of the groups which pulled out of the Governments now collapsed Safe To Be Me conference, said: From the British Medical Association and NHS England to the UK Council for Psychotherapy and the Royal Colleges of GPs and Psychiatrists, medical and psychiatric expertise is in agreement: conversion practices do not work, can cause lifelong trauma and must be banned.

With half of conversion practices happening in religious settings, LGBTQ+ people of faith make up one of the largest groups of victims. Thats why were heartened that numerous religious leaders, including the former Archbishop of Canterbury, Rowan Williams, recently wrote to the Prime Minister in support of a ban.

We must continue to look to religious leaders who, rather than turn a blind eye to abuse, wish to address the harms done to other people who deeply hold and value their religious beliefs and community.

Read the original here:

Christian group prepares legal challenge over conversion therapy ban - The Telegraph